SCHEMBL9684027

SCHEMBL9684027

CC1C(C(=O)O)CCC1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRR1 P24046 5/20 0.48
SLC1A2 P43004 5/20 0.41
SLC1A1 P43005 3/20 0.41
GABRR2 P28476 1/20 0.40
GRM2 Q14416 2/20 0.39
LMNA P02545 2/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
GRM8 O00222 1/20 0.37
GRM6 O15303 1/20 0.37
APEX1 P27695 1/20 0.37
GRM5 P41594 1/20 0.37
PMP22 Q01453 1/20 0.37
GRM1 Q13255 1/20 0.37
GRM3 Q14832 1/20 0.37
GRM4 Q14833 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3248675 0.94 GABRR1 (0.48) GABRR1SLC1A2SLC1A1GABRR2GRM2
SCHEMBL3630822 0.88 PEPD (0.46) GABRR1LMNAMEN1KMT2AALDH1A1
SCHEMBL6838216 0.84 GABRR1 (0.40) GABRR1SLC1A2SLC1A1GABRR2GRM2
SCHEMBL15514086 0.84 POLB (0.41) GABRR1SLC1A2SLC1A1GABRR2GRM2
SCHEMBL12904713 0.82 PEPD (0.46) GABRR1LMNAMEN1KMT2AALDH1A1
SCHEMBL23590197 0.82 GABRR1 (0.56) GABRR1SLC1A2SLC1A1GABRR2GRM2
SCHEMBL30811227 0.80 GABRR1 (0.37) GABRR1SLC1A2SLC1A1GABRR2GRM2
SCHEMBL20346208 0.79 GABRR1 (0.59) GABRR1SLC1A2SLC1A1GABRR2LMNA
SCHEMBL6938207 0.79 GABRR1 (0.59) GABRR1SLC1A2SLC1A1GABRR2LMNA
SCHEMBL339332 0.79 GABRR1 (0.59) GABRR1SLC1A2SLC1A1GABRR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11613702-B2 Liquid crystal composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-03-28 US disclosed
CN-106957662-B Liquid crystal composition 住友化学株式会社 2021-12-24 CN disclosed
US-11193065-B2 Liquid crystal composition, method of producing the same, and retardation film constituted from the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-12-07 US disclosed
US-20190276744-A1 LIQUID CRYSTAL COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2019-09-12 US disclosed
US-20170306234-A1 LIQUID CRYSTAL COMPOSITION, METHOD OF PRODUCING THE SAME, AND RETARDATION FILM CONSTITUTED FROM THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-26 US disclosed
US-20170145312-A1 LIQUID CRYSTAL COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-05-25 US disclosed
US-5096959-A Esterifying resin with cyclopentane- and cyclohexane dicarboxylic acids THE VALSPAR CORPORATION (US) 1992-03-17 US disclosed
WO-1991013938-A1 HYDROLYSIS RESISTANT ALKYD RESIN COATING COMPOSITION THE VALSPAR CORPORATION (US) 1991-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11613702-B2 Liquid crystal composition CCNL2, RCC2, LSS GABRR1 4092/4885SLC1A2 3262/4885SLC1A1 4069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.